慢性乙型肝炎是世界上最常见的传染病之一,据统计全世界有3.5亿人患此病。虽然群体免疫计划的实施已经开始减少了乙型肝炎病毒(HBV)的传播,但是,对于已经感染HBV的患者,治疗性的干预仍是控制肝病惟一的选择。以往α干扰素被认为是惟一有效的抗病毒治疗药物,但它的适应证有限,不良反应的发生率较高,且价格昂贵,限制了其广泛的应用。近年来,人们发现核苷类有很强的抗HBV作用,如拉米夫定、泛昔洛韦、Adefovir等,其中以拉米夫定研究较为广泛深入。拉米夫定(lamivudine)是治疗慢性乙型肝炎的新一类抗病 Chronic hepatitis B is one of the most common infectious diseases in the world and according to statistics, 350 million people in the world suffer from the disease. Although the implementation of the group immunization program has begun to reduce the spread of Hepatitis B virus (HBV), therapeutic intervention is still the only option for controlling liver disease in patients already infected with HBV. In the past, alpha-interferon was considered as the only effective antiviral therapy, but its indications were limited. The incidence of adverse reactions was high and its price was very high, limiting its wide application. In recent years, nucleosides have been found to have a strong anti-HBV effect, such as lamivudine, famciclovir, Adefovir, etc., of which lamivudine study more extensive. Lamivudine is a new class of disease-resistant drug used to treat chronic hepatitis B